clinical trial · NCT03069131
Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites
Centre Hospitalier Universitaire de Besancon·phase3·completed·n = 160
CirrhosisAscitesPeritonitisRifaximinPlacebo
brief summary
We wish to perform a multicenter, double-blind RCT with two parallel-group stratified on the center, comparing rifaximin to no rifaximin (placebo) for the primary prophylaxis of SBP in 'severe' cirrhotic patients with large ascites. The primary outcome will be the 12-month survival.
started
Jun 5, 2018
primary completion
Jun 3, 2022
completion
Mar 20, 2023
last updated
Apr 10, 2025
official title
A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol